Presepsin as an Early Biomarker for Ventilator-associated Pneumonia (VAP) Diagnosis in COVID-19 Patients: a Prospective Double Blind Observational Study

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

This study is observational and double blind. It evaluates the validity of presepsin (a serum biomarker of bacterial infections) as early biomarker of Ventilator Associated Pneumonia. It will be measured at day 0 (ICU admission) and every 48 hours in every patient with Sars-Cov 2 interstitial pneumonia requiring invasive mechanical ventilation (see inclusion ad exclusion criteria) until Day 30, ICU discharge or ICU death. There will be no change in clinical practice and in pneumonia diagnosis. We will examine how the elevation of presepsin level could be an early marker of ventilator associated pneumonia or a marker of bacterial pneumonia at ICU admission, before the microbiological results or clinical diagnosis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No
View:

• ICU patients with Sars Cov 2 interstitial pneumonia requiring invasive mechanical ventilation

Locations
Other Locations
Italy
SCDU Anestesia e Rianimazione, AOU San Luigi Gonzaga
Recruiting
Orbassano
Contact Information
Primary
Pietro Caironi
pietro.caironi@unito.it
0039 0119026510
Backup
Pietro Caironi
pietro.caironi@unito.it
00390119026510
Time Frame
Start Date: December 21, 2020
Estimated Completion Date: December 21, 2021
Participants
Target number of participants: 50
Authors
Guido Bussone, Pietro Caironi
Sponsors
Leads: San Luigi Gonzaga Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials